The company has traded on the OTC Bulletin Board under the symbol NTII since 1998, and will keep that symbol when listed on Nasdaq. • QLT Inc., of Vancouver, British Columbia, and Ciba Vision, the Atlanta-based eye care unit of Novartis AG, said the European Commission granted marketing authorization for Visudyne for the treatment of wet age-related macular degeneration

GCI also has begun a new arrangement with Quiagen Genomics Inc., of Seattle, to provide an integrated solution combining GCI's sample repository and database services with Qiagen's single nucleotide polymorphism genotyping services. • Genzyme General, of Cambridge, Mass., said the European Agency for the Evaluation of Medicinal Products has validated Genzyme's marketing authorization application for Fabrazyme (agalsidase beta) for Fabry disease, and that the Committee for Proprietary Medicinal

Geron's stock (NASDAQ:GERN) closed Wednesday at $21.062, up 25 cents. • Millennium & Ilex Partners LP, a joint venture of Millennium Pharmaceuticals Inc., of Cambridge, Mass., and Ilex Oncology Inc., of San Antonio, Texas, said that its marketing authorization application for Campath, a humanized monoclonal antibody, was accepted for review by the European Agency for the Evaluation of Medicinal Products

The test will allow physicians to screen for this mutation and adjust treatment accordingly. • QLT PhotoTherapeutics Inc., of Vancouver, British Columbia, and CIBA Vision Corp., of Atlanta, said the Committee for Proprietary Medicinal Products in Europe recommended granting marketing authorization for Visudyne (verteporfin) therapy to treat wet age-related macular degeneration...The favorable opinion now has to be endorsed by the European Commission before Myocet, formerly called Evacet, receives

In addition, the company raised $4 million with an unnamed institution and three accredited investors. • SangStat Medical Corp., of Fremont, Calif., said that a British court has rejected an attempt by Novartis Pharma AG, of Basel, Switzerland, to have the UK marketing authorization of SangStat's SangCya (cyclosporine) oral solution revoked...The judge ruled that the Medicines Control Agency (MCA) acted properly in granting the SangCya marketing authorization

The company plans to seek marketing authorizations for a tablet formulation of Periostat in the UK and other countries within the European Union. • Discovery Laboratories Inc., of Doylestown, Pa., received a warrant exercise notice from its largest shareholder, OrbiMed Advisors LLC, of New York

Atrix expects to introduce the product beginning in June after individual country marketing authorizations are issued

No financial terms were released. • Biopure Corp., of Cambridge, Mass., received marketing authorization for Oxyglobin (hemoglobin glutamer-200 bovine) from the European Commission for the treatment of canine anemia, a condition that threatens millions of dogs yearly...The extended agreement provides Select with an exclusive option to license the basic intellectual property relating to antigen presentation to dendritic cells. • Sonus Pharmaceuticals Inc., of Bothell, Wash., said that the

The company’s stock (NASDAQ:LJPC) gained 90.6 cents Tuesday, or 94 percent, to close at $1.875. • Ligand Pharmaceuticals Inc., of San Diego, said it submitted a marketing authorization application seeking European approval of Targretin capsules for treating patients with cutaneous T-cell lymphoma

submitted a centralized marketing authorization application to the European Union's European Agency for the Evaluation of Medicinal Products seeking clearance to market Peg-Intron (Peg-interferon alfa-2b) powder for the treatment of chronic hepatitis C in patients 18 years old or older with compensated liver disease. • Epimmune Inc., of San Diego, said data published in the recent issue of Nature Medicine support the company's approach to developing a vaccine for HIV

COR Therapeutics Inc., of South San Francisco, received a $12 million milestone payment from Schering-Plough Corp., of Madison, N.J., in connection with the marketing authorization granted to Integrilin in Europe

The company, in collaboration with the University of Virginia, will attempt to identify an oral agent for that indication. • Chiron Corp., of Emeryville, Calif., received marketing authorization through the mutual recognition procedure to sell its subunit influenza vaccine, Agrippal, in most Western European countries

Those countries, then, are expected to grant national marketing authorizations within six months. • ICAgen Inc., of Research Triangle Park, N.C., got an exclusive license from the State University of New York for novel ion channel genes, which are specific to certain regions of the brain and may be relevant to the treatment of central nervous system disorders

It also reduced triglycerides and blood pressure. • Isis Pharmaceuticals Inc., of Carlsbad, Calif., and Ciba Vision Corp., a division of Basel, Switzerland-based Novartis AG, received a positive recommendation in Europe on its marketing authorization application for Vitravene for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients

The beta sites represent a cross-section of potential users for Nanogen’s technology in the analysis of single-nucleotide polymorphisms and repetitive DNA sequences. • Sangstat Corp., of Menlo Park, Calif., filed for marketing authorization in the U.K

The action serves as the basis for European Commission approval, which is typically issued in four months and would result in a single marketing authorization valid in all 15 European Union member states. • Coulter Pharmaceutical Inc

The case is still pending. * Ligand Pharmaceuticals Inc., of San Diego, submitted a marketing authorization application in Europe for Panretin gel (alitretinoin) for the treatment of cutaneous lesions of patients with AIDS-related Kaposi's sarcoma

For 1997, PathoGenesis had a net loss of $33 million, or $2.10 per basic and diluted share. * SkyePharma plc, of London, reported that its partner Synthelabo SA, of Montrouge, France, submitted a marketing authorization application for a once-daily formulation of Xatral in France, Ireland, the Netherlands and the United Kingdom

Under the proposed agreement, Cytogen will receive an up-front cash payment and would continue to have its ProstaScint and OncoScint products manufactured there for a defined time. * Guilford Pharmaceuticals Inc., of Baltimore, reported that the Gliadel Wafer, the company's treatment for malignant brain cancer, received regulatory approval from the Canadian Health Protection Branch, and marketing authorization from the French Drug Agency, for use in the treatment of glioblastoma multiforme, a